Atrium Therapeutics Inc.
RNA | NASDAQ
$8.27
+$0.01 (+0.12%)
At close: Oct 30, 2026, 4:00 PM ET
$8.27
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 8:24 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Revenue | 18.62M |
Cost of Revenue | n/a |
Gross Profit | 18.62M |
Operating Income | -76.81M |
Interest Income | n/a |
Pretax Income | -76.83M |
Net Income | -76.68M |
Selling & General & Admin | 41.68M |
Research & Development | 53.76M |
Other Expenses | n/a |
Operating Expenses | 95.43M |
Interest Expense | n/a |
Selling & Marketing Expenses | n/a |
Cost & Expenses | 95.43M |
Income Tax Expense | -142K |
Shares Outstanding (Basic) | 17.11M |
Shares Outstanding (Diluted) | 17.11M |
EPS (Basic) | -4.48 |
EPS (Diluted) | -4.48 |
EBITDA | -76.5M |
EBIT | -76.83M |
Depreciation & Amortization | 323K |
Add to Watchlist
Select watchlists to add or remove RNA